

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Novartis Institutes for BioMedical Research, Inc. (Last) (First) (Middle) 250 MASSACHUSETTS AVENUE (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/27/2018	3. Issuer Name and Ticker or Trading Symbol Homology Medicines, Inc. [FIXX] <table style="width: 100%;"> <tr> <td style="width: 50%;">4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</td> <td style="width: 50%;">5. If Amendment, Date of Original Filed (Month/Day/Year)</td> </tr> <tr> <td> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) </td> <td> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person </td> </tr> </table>	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)	5. If Amendment, Date of Original Filed (Month/Day/Year)	Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)	5. If Amendment, Date of Original Filed (Month/Day/Year)					
Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person					

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(1)	Common Stock	1,979,226	(1)	D ⁽²⁾	

1. Name and Address of Reporting Person* Novartis Institutes for BioMedical Research, Inc. (Last) (First) (Middle) 250 MASSACHUSETTS AVENUE (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* NOVARTIS AG (Last) (First) (Middle) LICHTSTRASSE 35 (Street) BASEL V8 CH 4056 (City) (State) (Zip)		
--	--	--

Explanation of Responses:

- The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
- The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Series B Preferred Stock held directly by NIBRI.

Remarks:

[Novartis Institutes for BioMedical Research, Inc., By: /s/ Scott A. Brown, VP, General Counsel](#)

[Novartis AG, By: /s/ Stefan Thommen, Authorized Signatory, By: /s/ Susan Jones, Authorized Signatory](#)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.